Senores Pharmaceuticals Ltd.
NSE: SENORES
Prev Close
822.1
Open Price
827
Volume
139,131
Today Low / High
810 / 843.4
52 WK Low / High
440.3 / 876.5
Range
774 - 856
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 815.1, with a change of -7 (-0.85148%). The expected target range on the NSE is between 774 - 856. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
Senores Pharmaceuticals Ltd. Graph
Senores Pharmaceuticals Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Senores Pharmaceuticals Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 815.10, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 815.10 | 823.25 | 740.93 - 905.58 |
| 831.40 | 665.12 - 997.68 | ||
| 839.55 | 587.69 - 1,091.42 | ||
| Bearish Scenario | 815.10 | 806.95 | 726.25 - 887.64 |
| 798.80 | 639.04 - 958.56 | ||
| 790.65 | 553.45 - 1,027.84 |
Overview of Senores Pharmaceuticals Ltd.
ISIN
INE0RB801010
Industry
Drug Manufacturers - General
Vol.Avg
275,021
Market Cap
37,538,279,579
Last Dividend
0
Official Website
IPO Date
2024-12-30
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 382.80 Cr | 3.23 Cr | 1.41 Cr | 0.0037 | 5.06 Cr | 7.13 Cr | 72.81 Cr | 0.68 Cr | 0.19 | 107.78 Cr | 0.0018 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 105.38 Cr | 14.57 Cr | 5.07 Cr | 786.1900 Cr | 314.75 Cr | 2.45 Cr | 56.63 Cr | 259.76 Cr | 0.00 Cr | 0.00 Cr | 0.05 Cr | 240.7000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -45.9200 Cr | -429.4800 Cr | 573.1300 Cr | -203.4400 Cr | 97.7300 Cr | 105.3800 Cr | -157.5200 Cr | 70.5700 Cr | 121.0100 Cr | 0.0000 Cr | -19.2600 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 164.85 Cr | 67.02 Cr | 97.83 Cr | 0.5934 | 46.13 Cr | 31.66 Cr | 7.29 | 57.79 Cr | 0.1921 |
| 2025-09-30 | 153.36 Cr | 57.08 Cr | 96.28 Cr | 0.6278 | 41.41 Cr | 32.38 Cr | 6.54 | 54.92 Cr | 0.2111 |
| 2025-06-30 | 130.30 Cr | 61.36 Cr | 68.94 Cr | 0.5291 | 28.18 Cr | 19.73 Cr | 4.60 | 37.52 Cr | 0.1514 |
| 2025-03-31 | 98.76 Cr | 66.52 Cr | 32.24 Cr | 0.3264 | 14.16 Cr | 17.83 Cr | 0.00 | 30.03 Cr | 0.1805 |
| 2024-12-31 | 103.02 Cr | 40.70 Cr | 62.32 Cr | 0.6049 | 21.48 Cr | 17.18 Cr | 5.04 | 30.84 Cr | 0.1668 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 86.03 Cr | 274.34 Cr | 360.37 Cr | 2.25 Cr | 62.61 Cr | 663.81 Cr | 260.74 Cr | 1,288.15 Cr | 453.71 Cr |
| 2025-03-31 | 105.38 Cr | 280.12 Cr | 385.50 Cr | 241.88 Cr | 56.63 Cr | 8.45 Cr | 259.76 Cr | 14.57 Cr | 414.61 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - General
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Cipla Limited | CIPLA | ₹1,328.90 | ₹1,073,448,210,800.00 | ₹587,311.00 |
| Abbott India Limited | ABBOTINDIA | ₹26,395.00 | ₹560,875,326,290.00 | ₹4,981.00 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹2,577.90 | ₹436,711,815,049.00 | ₹57,059.00 |
| Gland Pharma Limited | GLAND | ₹1,840.50 | ₹303,234,196,532.00 | ₹53,810.00 |
| Pfizer Limited | PFIZER | ₹4,991.00 | ₹228,326,930,412.00 | ₹14,447.00 |
| Sanofi Consumer Healthcare India Ltd. | SANOFICONR | ₹4,046.80 | ₹93,200,321,110.00 | ₹3,660.00 |
| Sanofi India Limited | SANOFI | ₹4,024.50 | ₹92,686,738,239.00 | ₹10,395.00 |
| Marksans Pharma Limited | MARKSANS | ₹176.90 | ₹80,164,666,667.00 | ₹389,151.00 |
| Senores Pharmaceuticals Ltd. | SENORES | ₹815.10 | ₹37,538,279,579.00 | ₹139,131.00 |
| SMS Pharmaceuticals Limited | SMSPHARMA | ₹358.00 | ₹33,527,416,000.00 | ₹170,491.00 |
Key Executives
Gender: male
Year Born: 1966
Gender: male
Year Born:
Gender: male
Year Born: 1963
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1985
Gender: male
Year Born:
FAQs about Senores Pharmaceuticals Ltd.
The CEO is Swapnil Jatinbhai Shah.
The current price is ₹815.10.
The range is ₹440.3-876.5.
The market capitalization is ₹3,753.83 crores.
The P/E ratio is 34.84.
The company operates in the Healthcare sector.
Overview of Senores Pharmaceuticals Ltd. (ISIN: INE0RB801010) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹3,753.83 crores and an average daily volume of 275,021 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹0.